Clinical Trial Update: 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating 2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• 2-Hydroxybenzylamine (2-HOBA) (2-Hydroxybenzylamine)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21